D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Alexander I. Spira,David Spiegel,D. Ross Camidge,Adrianus J. de Langen,Tae Min Kim,Koichi Goto,Yasir Elamin,Elaine Shum,Karen L. Reckamp,Julia K Rotow,J. Goldberg,Shirish M. Gadgeel,Ticiana Leal,Faris P. Albayya,Sarah Fitzpatrick,Melinda Louie-Gao,Jagan Mohan R. Parepally,A. Zalutskaya,Helena A. Yu +18 more
TL;DR: Harmony, an ongoing, global phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of BLU-701 as a monotherapy or in combination with osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.
Posted ContentDOI
Bifunctional Small Molecules That Mediate the Degradation of Extracellular Proteins
David Caianiello,Mengwen Zhang,Jason Ray,Jake C Swartzel,Emily M J Branham,Egor Chirkin,Venkata R. Sabbasani,Angela Gong,David A. McDonald,Viswanathan Muthusamy,David Spiegel +10 more
TL;DR: In this paper, a class of modularly designed, bifunctional synthetic molecules called MoDE-As (Molecular Degraders of Extracellular proteins through the Asialoglycoprotein receptor (ASGPR)), which are capable of mediating the degradation of extracellular protein, was developed.
Journal ArticleDOI
Effect of vorinostat (V)-loaded PLGA nanoparticles (NP) surface modified with a PSMA ligand on prostate cancer (PC) cells.
Christopher J. Hoimes,R. P. Murelli,Wm. Kevin Kelly,A.X. Zhang,Christopher J. Cheng,R. J. Fields,David Spiegel,W. M. Saltzman +7 more
TL;DR: A NP was designed to deliver V to PC by polymeric NP that were SM with a ligand to prostate specific membrane antigen (PSMA) that was covalently modified to possess a glutamate urea with known pM Ki binding affinity to PSMA.
Journal ArticleDOI
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States
Daniel Auclair,Carol Mansfield,Mark A. Fiala,Ajai Chari,Craig E. Cole,Jonathan L. Kaufman,Gregory Orloff,David Spiegel,Jeffrey A. Zonder,Brennan Mange,Jennifer Yesil,Mehul Dalal,Joseph R. Mikhael +12 more
TL;DR: Patients with relapsed or refractory MM and their caregivers consider many factors including efficacy, toxicity, mode/frequency of administration, and cost in their decisions regarding treatment options.
Posted ContentDOI
Deterioration of Glutaraldehyde Crosslinked Heterograft Biomaterials due to Advanced Glycation End Product Formation and Serum Albumin Infiltration
Christopher A. Rock,Samuel Keeney,Andrey Zakharchenko,Hajime Takano,David Spiegel,Abba M. Krieger,Giovanni Ferrari,Robert J. Levy +7 more
TL;DR: It is concluded that AGE-BSA associated collagen structural disruption and deterioration of mechanical properties contribute to SVD.